| Results 1 - 50 of 699 | ||
| 1 2 3 4 5 6 7 8 9 10 > | ||
|
Shin Seung Han - - 2012
Abstract The principal objective of this study was to evaluate the effects of surface pre-treatment with platelet-rich plasma (PRP) on the cellular functions of human bone marrow stromal cells (hBMSCs). The surfaces of tissue culture plates (TCPs) were pre-treated by adding PRP followed by centrifugation to bring platelets closer to ...
|
||
|
Andia Isabel - - 2012
Introduction: At the beginning of the new millennium, there was a breakthrough in platelet-rich plasma (PRP) therapy for tissue repair. The mechanisms governing the effects of this therapy in joint pathology remain largely unexplored. Areas covered: This review is primarily based on PubMed and Web of Knowledge searches with the ...
|
||
|
Özdemir B - - 2011
Objective: Platelet-rich plasma (PRP) is considered to enhance bone formation especially at early stages of wound healing, depending on the limited and short life-span of platelets and growth factors. The aim of this study was to evaluate efficacy of double-application of PRP (DA-PRP) on bone healing in a rabbit calvarial ...
|
||
|
Park Hong-Bum - - 2011
The underlying rationale of platelet rich plasma (PRP) therapy is that an injection of concentrated PRP at the site of injury may promote tissue repair via cytokine release from platelets. The molecular mechanisms of PRP therapy in the skin wound healing process are not well understood at present, and would ...
|
||
|
Dassanayake Rohana P - - 2011
ABSTRACT: BACKGROUND: Classical scrapie is a naturally occurring transmissible spongiform encephalopathy of sheep and goats characterized by cellular accumulation of abnormal isoforms of prion protein (PrPSc) in the central nervous system and the follicles of peripheral lymphoid tissues. Previous studies have shown that the whole blood and buffy coat blood ...
|
||
|
Chen Jian-Chih - - 2011
OBJECTIVES: The aim of this study was to evaluate the performance of a 10wt% platelet-rich plasma (PRP) additive composite with calcium phosphate cement (CPC) in vitro and in vivo. METHODS: The in vitro testing of modulus, the apatite conversion rate, morphology, cell and alkaline phosphatase (ALP) activities, and in vivo ...
|
||
|
Iqbal Jameel - - 2011
This review examines the use of platelet-rich plasma (PRP) in the treatment of bone injuries and to stimulate bone formation. Studies examining both in vivo bone healing and in vitro actions of PRP on osteoblasts are reviewed. Overall, the available literature suggests that PRP does not appreciably impact bone healing ...
|
||
|
Bava Eric D - - 2011
Platelet-rich plasma (PRP) therapy is a recently developed technique that uses a concentrated portion of autologous blood to try to improve and accelerate the healing of various tissues. There is considerable interest in using these PRP products for the treatment of musculoskeletal disorders, particularly athletic injuries. Because PRP products are ...
|
||
|
Jo Chris Hyunchul - - 2011
Evidence suggesting that platelet-rich plasma (PRP) may have a potential for augmenting tissue healing has been growing recently. However, its local application technique has not been well established. Because of saline irrigation for keeping clear vision during arthroscopic procedures, it appears unreasonable to apply PRP in liquid form. We describe ...
|
||
|
Cho Jae-We - - 2011
Platelet-rich plasma (PRP) is derived from fresh whole blood, which contains a high concentration of platelets. Recently, PRP has been used for skin wound healing and rejuvenation. However, the molecular mechanisms underlying PRP-inducing wound healing processes are still largely unknown. The aim of this study is to evaluate the effect ...
|
||
|
Park Se-Il - - 2011
Platelets are involved in hemostasis, wound healing, and tumor growth. Autologous blood products are commonly used to facilitate healing in a variety of clinical surgery applications. Recently, it was shown that platelet-rich plasma (PRP) has more specific growth factors that participate in the healing process. This study investigated the expression ...
|
||
|
Shemirani Amir-Houshang - - 2011
We hypothesized that mean platelet volume (MPV), a reliable marker of platelet activation, might be elevated in primary Raynaud's phenomenon (PRP) even if there was no thrombotic complication in our subjects. In this retrospective-cohort study, we examined the clinical value of MPV in 200 patients with PRP and 116 clinical ...
|
||
|
Tohidnezhad Mersedeh - - 2011
Platelet-rich plasma (PRP) is a potent agent that improves soft tissue and bone healing. By the release of growth factors and cytokines, PRP is believed to locally boost physiologic healing processes. Recently, antimicrobial activity of PRP has been demonstrated against S. aureus strains. Major scientific effort is being put into ...
|
||
|
Cáceres Mónica - - 2011
OBJECTIVES: Although platelet-rich plasma (PRP) has been proposed as a therapeutic tool to enhance wound repair, the cellular and molecular mechanisms stimulated by this agent are still not completely understood. The present study was designed to characterize the effects of PRP and platelet-poor plasma (PPP) supernatants on cell responses involved ...
|
||
|
Deren Matthew E - - 2011
: Previous studies on Internet sites indicate that some Web-based material on sport-related orthopedic disorders is biased, misleading, and conveying inaccurate health messages. Our hypothesis was that Web-based content on platelet-rich plasma (PRP) therapy from commercial sites is frequently imbalanced, biased, and incorrect. : In this descriptive epidemiological study, an ...
|
||
|
Kurita Jiro - - 2011
Platelet-rich plasma (PRP) contains numerous growth factors that have angiogenic activities. However, the PRP-induced angiogenesis is limited by the short half-life period of growth factors. A new drug delivery system of biodegradable gelatin hydrogel was designed to achieve the controlled release of growth factors in PRP. The purpose of this ...
|
||
|
Takikawa Megumi - - 2011
BACKGROUND Treatments for alopecia are in high demand, but not all are safe and reliable. Dalteparin and protamine microparticles (D/P MPs) can effectively carry growth factors (GFs) in platelet-rich plasma (PRP). OBJECTIVE To identify the effects of PRP-containing D/P MPs (PRP&D/P MPs) on hair growth. METHODS & MATERIALS Participants were ...
|
||
|
Yang Hee Seok - - 2011
Platelet-rich plasma (PRP) contains growth factors that promote tissue regeneration. Previously, we showed that heparin-conjugated fibrin (HCF) exerts the sustained release of growth factors with affinity for heparin. Here, we hypothesize that treatment of skin wound with a mixture of PRP and HCF exerts sustained release of several growth factors ...
|
||
|
Gomez-Caro Abel - - 2011
This study investigated whether platelet-rich plasma (PRP) promotes healing and reduces anastomotic complications following airway surgery in a pig model. PRP was obtained by spinning down the animal's own blood (60 ml) and collecting the buffy coat containing platelets and white blood cells. Fifteen adult pigs were randomized into three ...
|
||
|
Shiraishi Noriyuki - - 2011
Because prion protein PrP-(23-98) was recently found to polymerize into amyloid-like and proteinase K-resistant spherical aggregates in the presence of NADPH plus copper ions, we tested to determine whether calreticulin (CRT) inhibits PrP-(23-98) aggregation in vitro. The results indicated that CRT suppressed PrP-(23-98) aggregation, and that CRT-mediated solubilization occurred in ...
|
||
|
Femia Eti Alessandra - - 2011
Light transmission aggregometry (LTA), the gold standard for the study of patients with defects of platelet function, is a poorly standardized technique. The guidelines that have been produced so far are largely based on consensus of experts, due to the absence of studies directly comparing different procedures. Therefore, ad hoc ...
|
||
|
Yuan Ting - - 2011
Leukocyte- and platelet-rich plasma (L-PRP) contains high concentrations of platelet, leukocytes and other bioactivities, which play an prominent role in both bone and soft tissue healing processes. Large numbers of studies provide evidence for application of L-PRP in experiments and clinical practice. It has been identified to improve cellular chemotaxis, ...
|
||
|
Del Corso Marco - - 2011
Platelet concentrates for surgical use are innovative tools of regenerative medicine, and were widely tested in oral and maxillofacial surgery. Unfortunately, the literature on the topic is contradictory and the published data are difficult to sort and interpret. In periodontology and dentoalveolar surgery, the literature is particularly dense about the ...
|
||
|
Dohan Ehrenfest David M - - 2011
In the field of platelet concentrates for surgical use, most products are termed Platelet-Rich Plasma (PRP). Unfortunately, this term is very general and incomplete, leading to many confusions in the scientific database. In this article, a panel of experts discusses this issue and proposes an accurate and simple terminology system ...
|
||
|
Bielecki Tomasz - - 2011
Platelet concentrates for topical use are innovative tools of regenerative medicine and their effects in various therapeutical situations are hotly debated. Unfortunately, this field of research mainly focused on the platelet growth factors, and the fibrin architecture and the leukocyte content of these products are too often neglected. In the ...
|
||
|
Cieslik-Bielecka Agata - - 2011
The use of platelet concentrates for topical use is of particular interest for the promotion of skin wound healing. Fibrin-based surgical adjuvants are indeed widely used in plastic surgery since many years in order to improve scar healing and wound closure. However, the addition of platelets and their associated growth ...
|
||
|
Mishra Allan - - 2011
Platelet rich plasma (PRP) is a powerful new biologic tool in sports medicine. PRP is a fraction of autologous whole blood containing and increased number of platelets and a wide variety of cytokines such as platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and transforming growth factor beta-1 ...
|
||
|
Alió Jorge L - - 2011
Blood derived products have demonstrated their capacity to enhance healing and stimulate the regeneration of different tissues and this enhancing effect is attributed to the growth factors and bioactive proteins that are synthesized and present in blood. Eye platelet rich plasma (E-PRP) provides higher concentration of essential growth factors and ...
|
||
|
Borzini Piero - - 2011
More or less after a decade of experimental and pioneering manual procedures to prepare platelet-rich plasma (PRP) for topical use, several portable and bedside devices were made available to prepare the PRP at the point-of-care. This technical opportunity increased the number of patients who got access to the treatment with ...
|
||
|
Jo Chris Hyunchul - - 2011
Background: Platelet-rich plasma (PRP) has been recently used to enhance and accelerate the healing of musculoskeletal injuries and diseases, but evidence is still lacking, especially on its effects after rotator cuff repair. Hypothesis: Platelet-rich plasma accelerates recovery after arthroscopic rotator cuff repair in pain relief, functional outcome, overall satisfaction, and ...
|
||
|
Smith Mary Atkinson - - 2011
Platelet-rich plasma (PRP), a portion of autologous blood containing concentrated platelets above baseline values, has gained recent popularity in the field of orthopaedics. Many orthopaedic surgeons feel that PRP plays an influential role in enhancing the healing process following soft-issue injuries in patients who have failed conservative management or in ...
|
||
|
Cho Hee Soon - - 2011
The objective of this study was to explore whether individual variations in the concentration of growth factors (GFs) influence the biologic effects of platelet-rich plasma (PRP) on human mesenchymal stem cells (HMSCs). The concentrations of 7 representative GFs in activated PRP (aPRP) were measured using ELISA. The effects of PRP ...
|
||
|
Hoggatt Julie - - 2011
Several hot topics relating to ortho-biologics were discussed at the 2011 Annual Meeting of the American Academy of Orthopedic Surgery (AAOS) in San Diego this February. Injecting a patient's own platelet-rich plasma (PRP) prior to orthopedic surgery was an important topic, and had its own forum devoted to debating its ...
|
||
|
Taylor Drew W - - 2011
OBJECTIVE:: To evaluate, through a systematic review of the current literature, the evidence-based outcomes of the use of platelet-rich plasma (PRP) for the treatment of tendon and ligament injuries. DATA SOURCES:: A search of English-language articles was performed in PubMed and EMBASE using keywords "PRP," "platelet plasma," and "platelet concentrate" ...
|
||
|
Parikh Bruhvi - - 2011
Periradicular surgery aims to achieve complete wound healing and regeneration of the periodontal unit. Platelet-rich plasma (PRP) is a platelet concentrate that is widely used to promote tissue healing, and bone induction through its various growth factors has been used in this study. This case report describes the use of ...
|
||
|
Rosenberger Laura H - - 2011
Heparin-induced thrombocytopenia is a common adverse effect of treatment with heparin resulting in paradoxical thromboses. An immunoglobulin G class "heparin-induced thrombocytopenia antibody" attaches to a heparin-platelet factor 4 protein complex. The antibody then binds to the FcγIIa receptor on the surface of a platelet, resulting in activation, consumption, and thrombocytopenia ...
|
||
|
Drouet Ludovic - - 2010
Platelet activation subsequent to the adhesion of platelets to the vascular wall results in the release of mediators that promote platelet aggregation, which plays a pivotal role in the development of the polyvascular atherosclerotic disease that can be referred to by the acronym 'ATIS' (AtheroThrombosIS). The currently available antiplatelet drugs ...
|
||
|
Ferreiro José Luis - - 2010
Patients with diabetes mellitus (DM) have accelerated atherosclerosis, which is the main underlying factor contributing to the high risk of atherothrombotic events in these patients. Atherothrombotic complications are the leading cause of morbidity and mortality in patients with DM. Among factors contributing to the prothrombotic condition which characterise patients with ...
|
||
|
Bernuzzi Gino - - 2010
Platelet gel is being ever more frequently used to promote healing of cutaneous ulcers. However, the factors that determine the often variable clinical outcome of this procedure are still incompletely understood. The aims of this study were to demonstrate that platelet gel, even when obtained under strictly controlled conditions, produces ...
|
||
|
Navarese Eliano Pio - - 2011
The aim of this study is to assess the relationship between cardiac autonomic dysfunction and increased platelet reactivity in patients with type 1 diabetes and whether alpha lipoic acid therapy (ALA) might improve both abnormalities in these patients. Cardiac autonomic function will be assessed by heart rate variability (HRV) analysis. ...
|
||
|
Stewart Judith C - - 2010
Diabetes confers an increased risk for cardiovascular effects of airborne particles. We hypothesized that inhalation of elemental carbon ultrafine particles (UFP) would activate blood platelets and vascular endothelium in people with type 2 diabetes. In a randomized, double-blind, crossover trial, 19 subjects with type 2 diabetes inhaled filtered air or ...
|
||
|
Santilli Francesca - - 2011
Patients with type 2 diabetes mellitus are characterized by increased incidence of cardiovascular events and enhanced thromboxane-dependent platelet activation. Urinary enzymatic TXA(2) metabolites (such as 11-dehydro-TXB(2)), reflecting the whole TXA(2) biosynthesis by platelet and extra-platelet sources, are significantly increased in diabetes with the absolute post-aspirin values of 11-dehydro-TXB(2) in diabetics ...
|
||
|
Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for ...
Wright Rohana J - - 2010
To examine the effects of acute insulin-induced hypoglycemia on inflammation, endothelial dysfunction, and platelet activation in adults with and without type 1 diabetes. We studied 16 nondiabetic adults and 16 subjects with type 1 diabetes during euglycemia (blood glucose 4.5 mmol/l) and hypoglycemia (blood glucose 2.5 mmol/l). Markers of inflammation, ...
|
||
|
Grantham N M - - 2010
This study aimed to determine the prevalence of anti-platelet use, and the extent to which contraindications to anti-platelet therapy prevent its use, in 726 diabetic patients attending a private clinic. Among those who reported a history of cardiovascular disease (CVD), 87.1% were on anti-platelet therapy. Of those without prior CVD ...
|
||
|
Neubauer H - - 2010
AIMS: Type 2 diabetes is a potent cardiovascular risk factor, associated with proinflammatory and prothrombotic processes. The purpose of this study was to investigate whether platelet-bound CD40-CD40L signalling, P-selectin expression and soluble CD40L were increased in patients with diabetes mellitus and can be normalized by improving glycaemic control. METHODS: Soluble ...
|
||
|
Jeong Seong-Ho - - 2010
Many clinical trials have shown the effectiveness of platelet releasate on chronic wound healing, but large volumes of blood must be aspirated from patients and a platelet separator is required. Moreover, in the case of using homologous platelets, time and effort are needed to locate a suitable donor, and the ...
|
||
|
Kocić Ivan - - 2010
The effects of various statins on platelet aggregation in blood samples from normal and diabetic rabbits were measured. All of the statins used in our study inhibited platelet aggregation by about 20% at 1 microM. Our results show that diabetes increased the rate of platelet aggregation from 48 +/- 5% ...
|
||
|
Jacobs Lotte - - 2010
BACKGROUND: Population studies suggest that persons with diabetes are more sensitive to the effects of particulate matter (PM) air pollution. However, the biological mechanisms of a possible prothrombotic effect underlying this enhanced susceptibility remain largely unknown. OBJECTIVE: We hypothesized that exposure to PM causes prothrombotic changes in persons with diabetes, ...
|
||
|
Santilli F - - 2010
BACKGROUND: Chronic hyperglycemia is a major contributor to in vivo platelet activation in diabetes mellitus. OBJECTIVES: To evaluate the effects of acarbose, an alpha-glucosidase inhibitor, on platelet activation and its determinants in newly diagnosed type 2 diabetic patients. METHODS: Forty-eight subjects (26 males, aged 61 +/- 8 years) with early ...
|
||
|
Konya Hiroyuki - - 2010
Vascular complications are a common factor determining morbidity and mortality of diabetic patients. In vitro studies have revealed that gliclazide has antiplatelet activities. To clinically assess this action, we measured the effects of gliclazide on platelet activities and abnormal fibrinolysis in patients with type 2 diabetes mellitus. We studied 14 ...
|
||
| 1 2 3 4 5 6 7 8 9 10 > | ||